Tepnel


Tepnel
Tepnel


“Base Pair played a critical part in getting Tepnel known and positioned right in the marketplace. Their insights in crafting the right messages along with their skills in motivating the market in buying into Tepnel were invaluable.”



Ben Matzilevich, CEO, Tepnel

Tepnel was created from the roll-up of seemingly disparate corporate assets, including an antibody manufacturer, pharmaceutical services, IVD diagnostics, and molecular assay developers for transplant diagnostics. Tepnel’s focus was to rapidly increase revenues and profits, increase its share price to a “fair market value” for an ultimate acquisition.

Base Pair enacted a communications plan that 1) helped the market understand Tepnel by tying its disparate functional parts into a cohesive whole “Molecular Diagnostics and Pharmaceutical Services”; 2) helped create awareness about the company among potential customers and new investors, and established future growth and development expectations; 3) leveraged key diagnostic product launches to generated excitement about Tepnel in the market.

Base Pair spurred the uptake of the Tepnel story among top market influencers in the biomedical sector. By proactively communicating Tepnel’s key messages in press releases and interviews with key media such as Bio Century, Clinca, Scrip, Nature, Bioworld Today, GEN and Medical Device Daily, the company went from a relatively unknown to a well recognized diagnostic products and pharma services company in under twelve months.

Tepnel succeeded in branding itself as a fast growing and innovative diagnostic product and pharma services company. Bolstered by the launch of unique diagnostics for Cystic Fibrosis and Downs Syndrome, Tepnel was acquired in March 2009 by GenProbe for 3x its market cap.